• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature: Adaptation and validation of an influenza a subtyping panel for detection of H1pdm09, H3 and H5 on a high-throughput RT-qPCR system

Commonground

Commonground

Senior Moderator
  • Published: 20 April 2026
​
Scientific Reports , Article number: (2026) Cite this article

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Abstract

Facing the emergence of highly pathogenic avian influenza virus (HPAIV) H5N1 clade 2.3.4.4b in birds and its circulation in dairy cattle, rapid and reliable assays to detect HPAIV infection in humans are needed in diagnostic laboratories worldwide. We adapted and evaluated the performance of a molecular influenza A subtyping assay for the detection of A(H1N1)pdm09, A(H3N2), A(H5) and a pan-influenza A target on a high-throughput, fully automated platform. Previously published target primers and probes (Panning et al., Terrier et al., and the World Health Organization) were modified for target inclusivity/exclusivity, and adapted to compatibility with the Roche cobas5800/6800/8800 system as multiplex reaction. To evaluate the analytical performance of the new subtyping assay external quality assessment (EQA) samples were used as standards and quantified by digital-PCR. Limits of detection determined by 95% probit analysis were 754.0 digital copies (dcp)/ml for A(H1N1)pdm09, 148.0 dcp/ml for A(H3N2), 156 dcp/ml for A(H5) and 45.2 dcp/ml for the influenza A pan-target. Linearity was assessed for each subtyping target over at least four log-steps (r[SUP]2[/SUP]: 0.9969–0.9998). The assay showed 100% agreement with EQA samples, eluates from the Friedrich Loeffler Institut (Germany) tested positive for different influenza A subtypes, and CE-IVD manual tests using 132 clinical samples. No false positives were detected in the exclusivity set. Our new subtyping assay is fully automated, easily scalable and can be used in surveillance and routine clinical settings enabling the detection of HPAIV infections in humans and may contribute to limit potential transmission chains at an early stage. Words: 250/250.
​
https://www.nature.com/articles/s41598-026-45563-5

​
 
You must log in or register to reply here.
Back
Top